What we do

For almost 50 years we’ve been creating high-quality medicines and making them accessible to the people who need them.

Learn more about how we do this across North America, MENA and Europe.

Investors

Together we are building a leading generics and specialty pharmaceutical company where everyone can thrive.

Learn more about our strategy, investment case and track record of success.

Responsibility

Learn more about how we put better health within reach, every day and make a difference to people’s lives.

Careers

We're looking for people who share our passion and want to help us make a real difference in the world.

Newsroom

Featured

Press Release, Corporate 15 December 2025

Hikma launches authorised generic of Nucynta® (tapentadol) in the US Press Release, Product 25 February 2026 Hikma launches authorised generic of Nucynta® (tapentadol) in the US
Notice of results Press Release, Financial Results 03 February 2026 Notice of results
Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 19 January 2026 Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively
Hikma achieves B scores in Climate Change and Water Security in 2025 CDP assessment Press Release, Corporate 15 January 2026 Hikma achieves B scores in Climate Change and Water Security in 2025 CDP assessment